Radiopharm Theranostics Receives FDA IND Approval for Phase 2b Imaging Trial in Brain Metastases

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that it…